Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma
暂无分享,去创建一个
Boram Lee | Yoon-La Choi | Joungho Han | Jhingook Kim | M. Hong | Yoon-La Choi | Mao Mao | Mao Mao | Joungho Han | Ji-Young Song | Kyungsoo Jung | Ji-Young Song | Jhingook Kim | Seung Eun Lee | Maruja E Lira | Boram Lee | Maruja Lira | Mineui Hong | Kyungsoo Jung | Ji-Young Song | Ji-Young Song
[1] M. Santoro,et al. Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma. , 1994, Oncogene.
[2] Seungbok Lee,et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. , 2012, Genome research.
[3] S. Ou,et al. Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non–Small-Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[4] T. Kohno,et al. ROS1-Rearranged Lung Cancer: A Clinicopathologic and Molecular Study of 15 Surgical Cases , 2013, The American journal of surgical pathology.
[5] C. Couture,et al. Immunohistochemistry is a Reliable Screening Tool for Identification of ALK Rearrangement in Non–Small-Cell Lung Carcinoma and is Antibody Dependent , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[6] A. Iafrate,et al. Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population , 2009, Clinical Cancer Research.
[7] Doron Lipson,et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies , 2012, Nature Medicine.
[8] A. Iafrate,et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. , 2008, Cancer research.
[9] Lei Wang,et al. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features. , 2014, Lung cancer.
[10] M. Santoro,et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas , 1990, Cell.
[11] H. Aburatani,et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.
[12] M. Villalona-Calero,et al. RET fusion genes in non-small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Laura A. Sullivan,et al. Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer , 2007, Cell.
[14] T. Kohno,et al. RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis , 2014, British Journal of Cancer.
[15] S. Ha,et al. Cytologic Features of ALK-Positive Pulmonary Adenocarcinoma , 2013, Korean journal of pathology.
[16] Shibing Deng,et al. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer. , 2014, The Journal of molecular diagnostics : JMD.
[17] A. Carrano,et al. Human ret proto-oncogene mapped to chromosome 10q11.2. , 1989, Oncogene.
[18] H. Ji,et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] P. Jänne,et al. ROS1 Immunohistochemistry for Detection of ROS1-Rearranged Lung Adenocarcinomas , 2013, The American journal of surgical pathology.
[20] Yasushi Totoki,et al. KIF5B-RET fusions in lung adenocarcinoma , 2012, Nature Medicine.
[21] L. Tanoue,et al. Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer , 2012 .
[22] Marina N. Nikiforova,et al. Molecular genetics and diagnosis of thyroid cancer , 2011, Nature Reviews Endocrinology.
[23] J. Acquaviva,et al. The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. , 2009, Biochimica et biophysica acta.
[24] Takashi Yamasaki,et al. Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma , 2010, Journal of Clinical Pathology.
[25] A. Tsao,et al. ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers , 2012 .
[26] A. Shaw,et al. Novel targets in non-small cell lung cancer: ROS1 and RET fusions. , 2013, The oncologist.
[27] Jeffrey W. Clark,et al. ROS1 rearrangements define a unique molecular class of lung cancers. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] T. Gu,et al. Analysis of Receptor Tyrosine Kinase ROS1-Positive Tumors in Non–Small Cell Lung Cancer: Identification of a FIG-ROS1 Fusion , 2012, Clinical Cancer Research.
[29] A. Iafrate,et al. Spectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never Smokers , 2011, PloS one.
[30] E. Brambilla,et al. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas. , 2014, Lung cancer.
[31] N. Saijo. Present Status and Problems on Molecular Targeted Therapy of Cancer , 2012, Cancer research and treatment : official journal of Korean Cancer Association.
[32] Lu Wang,et al. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. , 2013, Cancer discovery.
[33] S. Digumarthy,et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] H. Sasaki,et al. RET expression and detection of KIF5B/RET gene rearrangements in Japanese lung cancer , 2012, Cancer medicine.
[35] T. Kohno,et al. Comprehensive Histologic Analysis of ALK-Rearranged Lung Carcinomas , 2011, The American journal of surgical pathology.
[36] Caicun Zhou,et al. KIF5B‐RET fusions in Chinese patients with non–small cell lung cancer , 2013, Cancer.
[37] Yuki Togashi,et al. RET, ROS1 and ALK fusions in lung cancer , 2012, Nature Medicine.